New Amsterdam Pharma: Funding, Investors & Team (Sep 2026)
Incorporated in 2019, NewAmsterdam Pharma is a clinical-stage organization dedicated to the study and creation of game-changing treatments for cardio-metabolic disorders. Its goal is to enhance patient care in groups when conventional treatments have failed or are tolerated. A new, selective inhibitor of the cholesteryl ester transfer protein (CETP), obicetrapib (TA-8995), was purchased by NewAmsterdam from Amgen in April 2020. For patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) who are on maximally tolerated statin therapy or who cannot be treated optimally with currently available lipid-lowering therapy, the company is looking into obicetrapib as the preferred LDL-c lowering therapy. The Series A fundraising round for NewAmsterdam, which totaled $196 million (€160 million) in January 2021, will support the whole Phase 3 development of Obicetrapib.
New Amsterdam Pharma has raised $429M across 2 funding rounds on record, the most recent an undisclosed round of $235M announced in Nov 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
New Amsterdam Pharma Company Profile and Key Stats
Latest funding round on record: Nov 2022.
New Amsterdam Pharma Funding Rounds
New Amsterdam Pharma raised $194M in a Series A announced in Jan 2021.
1.8 years later, an undisclosed round of $235M was announced in Nov 2022.
New Amsterdam Pharma Founders and Leadership Team
Contact details for the New Amsterdam Pharma team: 1 of 1 has an email address on file.
Start 14-day free trial →New Amsterdam Pharma Funding Compared to Other Biotechnology Startups
New Amsterdam Pharma's latest round of $235M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like New Amsterdam Pharma in Biotechnology and Naarden
Companies Similar to New Amsterdam Pharma
The Protein Brewery is a high-tech company that specializes in developing and making animal-free- based…
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral…
Onward is creating an Implantable Neuro-stimulation System (INS) that includes real-time motion feedback and…
Scinvivo is a medical technology company. Scinvivo is involved in bladder cancer medical needs. They provide…
Revyve produces animal-free food ingredients from microorganisms. The company's premium ingredients include…
Merus is dedicated to creating superior treatments for cancer patients and potentially finding a cure. Our…
Salvia BioElectronics is dedicated to creating new neuromodulation devices to help treat migraines. They are…
We are a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial…
QurieGen is a biotechnology company that speeds up the process of finding and creating new drugs.
Protix Biosystems is a biometrics company that offers a range of products which enable its customers to…
QDI Systems is a startup company that engages in the development of advanced imaging devices for medical…
BIMINI Biotech, a startup established in 2019 in Leiden, The Netherlands, focuses on creating groundbreaking…
New Amsterdam Pharma Funding FAQs
What does New Amsterdam Pharma do?
Incorporated in 2019, NewAmsterdam Pharma is a clinical-stage organization dedicated to the study and creation of game-changing treatments for cardio-metabolic disorders. Its goal is to enhance patient care in groups when conventional treatments have failed or are tolerated. A new, selective inhibitor of the cholesteryl ester transfer protein (CETP), obicetrapib (TA-8995), was purchased by NewAmsterdam from Amgen in April 2020. For patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) who are on maximally tolerated statin therapy or who cannot be treated optimally with currently available lipid-lowering therapy, the company is looking into obicetrapib as the preferred LDL-c lowering therapy. The Series A fundraising round for NewAmsterdam, which totaled $196 million (€160 million) in January 2021, will support the whole Phase 3 development of Obicetrapib.
How much funding has New Amsterdam Pharma raised?
New Amsterdam Pharma has raised $429M across 2 rounds on record. The most recent is an undisclosed round of $235M announced in Nov 2022.
When did New Amsterdam Pharma last raise funding?
New Amsterdam Pharma's most recent funding round on record is an undisclosed round of $235M, announced in Nov 2022.
Who is the CEO of New Amsterdam Pharma?
Michael Davidson is listed as CEO at New Amsterdam Pharma.
Where is New Amsterdam Pharma headquartered?
New Amsterdam Pharma is based in Naarden, Noord-Holland, Netherlands.
How many employees does New Amsterdam Pharma have?
New Amsterdam Pharma is in the 11-50 employee band.
How does New Amsterdam Pharma's funding compare to other Biotechnology startups?
New Amsterdam Pharma's latest round of $235M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's New Amsterdam Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for New Amsterdam Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.